Standard BioTools Inc, listed as NASDAQ:LAB, is gearing up to announce its Q2 2025 earnings results on August 11, 2025. Market analysts anticipate the company to report a revenue of $39.82 million for Q2 2025, with an expected loss of -$0.08 per share. Looking ahead to the full year 2025, revenue projections stand at $169.15 million, while the estimated earnings per share are anticipated to be -$0.28. For more comprehensive estimates, interested parties can refer to the Forecast page for detailed data.
Estimates for Standard BioTools Inc have shown a downward trend recently. The revenue forecast for the entire year of 2025 has decreased slightly from $169.20 million to $169.15 million, and for 2026, it has shifted from $190.80 million to $189.75 million over the past 90 days. Similarly, earnings estimates have dipped from -$0.26 per share to -$0.28 for 2025, while remaining steady at -$0.17 per share for 2026 during the same period.
Analyzing the company’s performance in the previous quarter ending March 31, 2025, Standard BioTools Inc managed to outperform expectations. The actual revenue of $40.80 million exceeded the projected $40.10 million by 1.73%, while the earnings per share of -$0.07 fared better than the estimated -$0.075 by 6.67%. Despite this positive outcome, the company experienced a 3.77% decline in its stock price on the day of the earnings release.
Two analysts have provided one-year price targets for Standard BioTools Inc, with an average target price of $1.93. This average target implies a potential upside of 49.22% from the current price of $1.29. Conversely, GuruFocus estimates the GF Value for the company in one year to be $0.87, suggesting a downside of 32.56% from the current stock price of $1.29.
Based on the consensus recommendation from three brokerage firms, Standard BioTools Inc currently holds an average brokerage recommendation rating of 2.0, indicating an “Outperform” status. This rating scale ranges from 1 to 5, with 1 representing Strong Buy and 5 indicating Sell. It’s important to note that these assessments are based on historical data and analyst projections and do not constitute personalized financial advice.
In conclusion, the outlook for Standard BioTools Inc (LAB) Q2 2025 earnings is eagerly awaited by investors and analysts alike. While recent estimates show a slight decline, the company’s past performance suggests a potential to exceed expectations. The stock’s one-year price targets and analyst recommendations further paint a picture of cautious optimism in the market regarding Standard BioTools Inc’s future prospects.
Key Takeaways:
– Standard BioTools Inc is expected to announce its Q2 2025 earnings soon, with revenue and earnings estimates available for investors to review.
– Recent trends show a slight decline in revenue and earnings forecasts for the company for 2025 and 2026.
– Despite a decline in stock price post the previous quarter’s earnings release, Standard BioTools Inc has shown positive performance against expectations.
– Analysts’ one-year price targets and brokerage firm recommendations indicate a mixed but cautiously optimistic sentiment towards Standard BioTools Inc’s future performance.
Read more on finance.yahoo.com